<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Blockade of the renin-angiotensin system with <z:chebi fb="0" ids="35457">angiotensin-converting enzyme inhibitors</z:chebi> or <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> receptor blockers has been shown to lessen the rate of decrease in glomerular filtration rate in patients with diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>STUDY DESIGN: A multicenter open-label randomized controlled trial to compare the efficacy of combining the <z:chebi fb="0" ids="35457">angiotensin-converting enzyme inhibitor</z:chebi> <z:chebi fb="0" ids="43755">lisinopril</z:chebi> and the <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> receptor blocker <z:chebi fb="0" ids="5959">irbesartan</z:chebi> with that of each drug in monotherapy (at both high and equipotent doses) in slowing the progression of type 2 diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>SETTING &amp; POPULATION: 133 patients with type 2 diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> (age, 66 ± 8 years; 76% men) from 17 centers in Spain </plain></SENT>
<SENT sid="3" pm="."><plain>INTERVENTION: Patients were randomly assigned (1:1:2) to <z:chebi fb="0" ids="43755">lisinopril</z:chebi> (n = 35), <z:chebi fb="0" ids="5959">irbesartan</z:chebi> (n = 28), or the combination of both (n = 70) </plain></SENT>
<SENT sid="4" pm="."><plain>OUTCOMES: The primary composite outcome was a &gt;50% increase in baseline serum <z:chebi fb="0" ids="16737">creatinine</z:chebi> level, <z:hpo ids='HP_0003774'>end-stage renal disease</z:hpo>, or <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Baseline values for mean estimated glomerular filtration rate and blood pressure were 49 ± 21 mL/min/1.73 m(2) and 153 ± 19/81 ± 11 mm Hg </plain></SENT>
<SENT sid="6" pm="."><plain>Mean geometric baseline <z:hpo ids='HP_0000093'>proteinuria</z:hpo> was protein excretion of 1.32 (95% CI, 1.10-1.62) g/g <z:chebi fb="0" ids="16737">creatinine</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>After a median follow-up of 32 months, 21 (30%) patients in the combination group, 10 (29%) in the <z:chebi fb="0" ids="43755">lisinopril</z:chebi> group, and 8 (29%) in the <z:chebi fb="0" ids="5959">irbesartan</z:chebi> group reached the primary outcome </plain></SENT>
<SENT sid="8" pm="."><plain>HRs were 0.96 (95% CI, 0.44-2.05; P = 0.9) and 0.90 (95% CI, 0.39-2.02; P = 0.8) for the combination versus the <z:chebi fb="0" ids="43755">lisinopril</z:chebi> and <z:chebi fb="0" ids="5959">irbesartan</z:chebi> groups, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>There were no significant differences in <z:hpo ids='HP_0000093'>proteinuria</z:hpo> reduction or blood pressure control between groups </plain></SENT>
<SENT sid="10" pm="."><plain>The number of adverse events, including <z:hpo ids='HP_0002153'>hyperkalemia</z:hpo>, was similar in <z:hpo ids='HP_0000001'>all</z:hpo> 3 groups </plain></SENT>
<SENT sid="11" pm="."><plain>LIMITATIONS: The study was not double blind </plain></SENT>
<SENT sid="12" pm="."><plain>The sample size studied was small </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: We were unable to show a benefit of the combination of <z:chebi fb="0" ids="43755">lisinopril</z:chebi> and <z:chebi fb="0" ids="5959">irbesartan</z:chebi> compared to either agent alone at optimal high doses on the risk of progression of type 2 diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
</text></document>